Collaboration & Consolidation Promoting Indian Influenza Market Growth

?Indian Influenza market is witnessing strategic collaborations that is propelling its growth? says RNCOS

Influenza Vaccines are gaining a lot of interest from researchers worldwide. Their ability to protect against flu and its potentially serious complications is instilling fascination among big pharmaceutical companies. In order to cash in on this technology, pharmaceutical giants are indulging in strategic moves, such as collaborations, mergers and acquisitions. Most of these moves are being made in order to combine technologies and capabilities from other companies with inherent ones for the development of influenza vaccines.

According to our report entitled ?Indian Influenza Market By Product Type (Vaxigrip, Influvac)-Forecast 2020?, increasing mergers, collaborations and partnerships are, in turn, aiding the influenza vaccine market in India to grow at a faster pace. For instance, Novavax has a mutual cooperation agreement with Cadila Pharmaceuticals of India for the development and manufacturing of influenza vaccines in India. These influenza vaccines are genetically engineered by Novavax. Under this joint venture which is now known as CPL-Biologics (CPL-B), a production facility has been set up in India that could produce over 60 Million Doses of influenza vaccines every year. This joint business enterprise not only gave Novavax a presence in India, but also the reach to a high-tech manufacturing facility.

Moreover, in 2015, Cipla signed an agreement with Serum Institute of India to exclusively market flu vaccine Nasovac-S in India. Under this agreement, Serum Institute would develop and manufacture the vaccine, and Cipla would exclusively market it in India. The vaccine would be manufactured in Serum Institute?s world class production facilities approved by the WHO. By making collaborations with each other, these companies share the technology with each other; expand their market in local as well as international regions, thus simplifying the influenza vaccine development procedure.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM895.htm

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

ABOUT RNCOS

RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.

Company :-RNCOS E-Services Pvt. Ltd.

User :- Shushmul Maheshwari

Email :-press@rncos.com

Phone :-24700-24700-4224700

Mobile:- 120-4224700

Url :- http://www.rncos.com